Delta Financial Group Inc. Takes $1.23 Million Position in Stryker Co. (NYSE:SYK)

Delta Financial Group Inc. purchased a new stake in shares of Stryker Co. (NYSE:SYK) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 3,402 shares of the medical technology company’s stock, valued at approximately $1,225,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Ascent Wealth Partners LLC increased its holdings in shares of Stryker by 4.3% during the fourth quarter. Ascent Wealth Partners LLC now owns 29,586 shares of the medical technology company’s stock valued at $10,652,000 after acquiring an additional 1,212 shares in the last quarter. MONECO Advisors LLC increased its holdings in shares of Stryker by 5.0% during the fourth quarter. MONECO Advisors LLC now owns 2,035 shares of the medical technology company’s stock valued at $733,000 after acquiring an additional 96 shares in the last quarter. Howard Capital Management Inc. increased its holdings in shares of Stryker by 5.2% during the fourth quarter. Howard Capital Management Inc. now owns 2,201 shares of the medical technology company’s stock valued at $792,000 after acquiring an additional 108 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Stryker by 2.9% during the fourth quarter. First Horizon Advisors Inc. now owns 2,146 shares of the medical technology company’s stock valued at $773,000 after acquiring an additional 61 shares in the last quarter. Finally, Pinnacle Financial Partners Inc increased its holdings in Stryker by 1.3% in the 4th quarter. Pinnacle Financial Partners Inc now owns 6,795 shares of the medical technology company’s stock worth $2,447,000 after buying an additional 84 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 1.0 %

SYK stock opened at $382.59 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market cap of $145.99 billion, a P/E ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The business’s 50-day moving average price is $378.07 and its 200-day moving average price is $368.99.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the firm posted $3.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio is presently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Analysts Set New Price Targets

SYK has been the subject of several research analyst reports. Truist Financial lifted their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. BTIG Research lifted their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Finally, Wells Fargo & Company lifted their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.